drugset / Trial / NCT02042690
Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Phase 3
Completed
131 enrolled
Peking University
Chinese PLA General Hospital · collabPeking Union Medical College Hospital · collabPeking University Aerospace Center Hospital · collabThe First Affiliated Hospital of Soochow University · collabUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The survival of adult patients with standard-risk acute lymphoblastic leukemia(ALL) need to improve. We want to compare the efficacy of haplo-identical hematopoietic stem cell transplantation (HSCT) with chemotherapy for adult(age:18-39 years old) ALL patients in first phase of complete remission (CR1)
Timeline
- Start
- 2014-07
- Primary completion
- 2018-02
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 1 mg/kg | — |
| Comparator | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Comparator | Cytarabine | Small molecule | — | Intravenous |
| Comparator | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Comparator | Epirubicin | Small molecule | 60 mg/m2 | — |
| Comparator | MERCAPTOPURINE ANHYDROUS | Small molecule | 60 mg/m2 | Oral |
| Comparator | Methotrexate | Small molecule | 20 mg/m2 | Intravenous |
| Comparator | Vindesin | Unknown | 4 mg | Intravenous |